Crizotinib in bronchial carcinoma: New data not informative
Crizotinib (trade name: Xalkori) has been available since 2012 for patients with advanced non-small cell lung cancer (bronchial carcinoma) with high activity of the enzyme anaplastic lymphoma kinase (ALK) who have already ...
Oct 6, 2016
0
1